Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Assets (2016 - 2025)

Historic Assets for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $12.4 million.

  • Traws Pharma's Assets rose 3924.57% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 3924.57%. This contributed to the annual value of $25.0 million for FY2024, which is 1004.72% up from last year.
  • Per Traws Pharma's latest filing, its Assets stood at $12.4 million for Q3 2025, which was up 3924.57% from $15.6 million recorded in Q2 2025.
  • Over the past 5 years, Traws Pharma's Assets peaked at $60.0 million during Q3 2021, and registered a low of $8.9 million during Q3 2024.
  • Its 5-year average for Assets is $32.9 million, with a median of $30.5 million in 2023.
  • In the last 5 years, Traws Pharma's Assets soared by 17758.43% in 2021 and then tumbled by 6695.02% in 2024.
  • Quarter analysis of 5 years shows Traws Pharma's Assets stood at $55.5 million in 2021, then decreased by 29.03% to $39.4 million in 2022, then tumbled by 42.39% to $22.7 million in 2023, then rose by 10.05% to $25.0 million in 2024, then tumbled by 50.15% to $12.4 million in 2025.
  • Its Assets was $12.4 million in Q3 2025, compared to $15.6 million in Q2 2025 and $19.1 million in Q1 2025.